The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2′-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes-Reference-Cited by-同舟云学术

The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2′-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes

Published:2011-09 Issue:5 Volume:82 Page:441-452
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Vande Voorde Johan,Liekens Sandra,McGuigan Christopher,Murziani Paola G.S.,Slusarczyk Magdalena,Balzarini Jan

Funder

NuCana BioMed, the Concerted Actions of the K.U.Leuven

Fonds voor Wetenschappelijk Onderzoek (FWO) Vlaanderen

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference46 articles.

1. Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation;Hatse;Biochem Pharmacol,1999

2. Nucleoside analogues and nucleobases in cancer treatment;Galmarini;Lancet Oncol,2002

3. Role of platelet derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity and potential role of deoxyribose-1-phosphate;de Bruin;Nucleosides Nucleotides Nucleic Acids,2004

4. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts;Ishikawa;Biochem Pharmacol,1998

5. Capecitabine: a review;Walko;Clin Ther,2005

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301);Journal of Experimental & Clinical Cancer Research;2024-04-02

2. An insight into thymidylate synthase inhibitor as anticancer agents: an explicative review;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-03-06

3. A Phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301);2023-11-15

4. Advanced prodrug strategies in nucleoside analogues targeting the treatment of gastrointestinal malignancies;Frontiers in Cell and Developmental Biology;2023-04-18

5. The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent;Cancer Chemotherapy and Pharmacology;2023-03-31